Hjem › Blodkreft › Connecticut
Kliniske studier for Blodkreft i Connecticut
8 studier for Blodkreft søker deltakere på steder i Connecticut.
Byer i Connecticut
Offisiell studietekst (engelsk)
Genomic Profiling in Cancer Patients
- St. Vincent (Data Collection Only), Bridgeport
- Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford
- Norwalk Hospital, Norwalk
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT01775072Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT03816345Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04242095Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Yale University Medical Center, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06823167A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Yale New Haven Hospital, New Haven
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.